Kennedy rewrites rules for membership on US vaccine advisory panel

Published 04/06/2026, 05:41 PM
Updated 04/06/2026, 05:42 PM
© Reuters.

By Julie Steenhuysen and Nate Raymond

CHICAGO, April 6 (Reuters) - U.S. Health Secretary Robert F. Kennedy Jr. is rewriting the rules of membership for a key vaccine advisory panel, according to a document published by his department on Monday, after a judge last month declared most of his prior selections unqualified and put their decisions on hold.

The Advisory Committee on Immunization Practices, which advises the Centers for Disease Control and Prevention on the use of vaccines, had been a major tool in Kennedy’s efforts to reshape U.S. vaccine policy.

In a March 16 decision, Boston-based U.S. District Judge Brian Murphy concluded that ACIP had been unlawfully reconstituted after Kennedy, a longtime anti-vaccine activist, last year removed and replaced all 17 independent experts who previously served on the panel, adding several members who share his controversial vaccine views.

In his decision, Murphy concluded that Kennedy’s ACIP panel violated the Federal Advisory Committee Act and repeatedly pointed to the panel’s charter, which required that its members have expertise in the use and research of vaccines and immunization practices.

On Monday, the Department of Health and Human Services led by Kennedy published a renewal of the charter that broadens the list of expertise for individuals who could serve on that panel, which makes recommendations impacting the use of vaccines, including the U.S. childhood immunization schedule.

A previous version of the charter signed by Kennedy in December stipulated that panel members should be knowledgeable about immunization practices and public health, and have expertise using vaccines in clinical practice or preventive medicine or have expertise in vaccine research, or in vaccine efficacy and safety.

Two former ACIP members appointed by previous administrations said the new charter appears to broaden the requirements for membership, listing examples of specialists in biostatistics and toxicology.

In his decision, Murphy said the members Kennedy appointed were "distinctly unqualified," with only six of the 15 members having any meaningful experience in vaccines.

HHS spokesman Andrew Nixon downplayed the significance of the changes, saying the ACIP charter renewal and publication "are routine statutory requirements and do not signal any broader policy shift."

The revamped charter followed a letter sent to Kennedy on March 25 by attorney Aaron Siri representing Informed Consent Action Network, a group critical of vaccine safety and mandates, recommending changes to the ACIP charter.

According to a press release on the ICAN website promoting the letter, the group called on Kennedy to "clarify committee member criteria" and argued that all 13 of the ACIP members whose qualifications were challenged in Murphy’s decision "do have the requisite experience."

So far, the Trump administration has not appealed Murphy’s ruling, but still has time to do so under a 60-day window.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.